Stem Cell Radiotherapy and Temozolomide for Newly Diagnosed High-grade Glioma (STRONG)
STRONG Trial - Stem Cell Radiotherapy (ScRT) and Temozolomide for Newly Diagnosed High-grade Glioma (HGG): A Prospective, Phase I/II Trial
Sponsor: Beth Israel Medical Center
Terminated
Poor Accural
Other terminated trials from Beth Israel Medical Center
Other Anaplastic Astrocytoma trials with similar outcome
This NA trial investigates Anaplastic Astrocytoma and Brain Tumors and is currently terminated or withdrawn. Beth Israel Medical Center leads this study, which shows 7 recorded versions since 2013 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.
Status Flow
Change History
7 versions recorded-
Sep 2024 — Present [monthly]
Terminated NA
-
Jul 2024 — Sep 2024 [monthly]
Terminated NA
-
Jan 2021 — Jul 2024 [monthly]
Terminated NA
-
Jun 2018 — Jan 2021 [monthly]
Terminated NA
-
Jul 2017 — Jun 2018 [monthly]
Terminated NA
Phase: PHASE1_PHASE2 → NA
▶ Show 2 earlier versions
-
Feb 2017 — Jul 2017 [monthly]
Terminated PHASE1_PHASE2
Status: Recruiting → Terminated
-
Jan 2017 — Feb 2017 [monthly]
Recruiting PHASE1_PHASE2
First recorded
Dec 2013
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Beth Israel Medical Center
- St. Luke's-Roosevelt Hospital Center
For direct contact, visit the study record on ClinicalTrials.gov .